我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

复方斑蝥注射液对中晚期结直肠癌TGF-β1表达影响的前瞻性临床研究(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2016年04期
页码:
47-50
栏目:
临床研究
出版日期:
2016-08-01

文章信息/Info

Title:
Study on the Compound Cantharis Injection TGF-beta1 Expression in Patientswith Locally Advanced Colorectal Cancer
作者:
刘冰心1唐世锋2李有杰1王璐1孙铮迪1臧传鑫1孙长岗2
1.山东中医药大学,山东 济南 250355;2.潍坊市中医院,山东 潍坊 261041
Author(s):
LIU Bingxin1 TANG Shifeng2 LI Youjie1 WANG Lu1 SUN Zhengdi1 ZANG Chuanxin1 SUN Changgang2
1. Shandong University of Traditional Chinese Medicine, Jinan 250355, China;2. Weifang Municipal Hospital of Traditional Chinese Medicine, Weifang 261041, China
关键词:
复方斑蝥注射液 结直肠癌 TGF-β1 临床疗效
Keywords:
compound cantharis injection colorectal cancer TGF-beta1 clinical efficacy
分类号:
R273
DOI:
10.19288/j.cnki.issn.1000-2723.2016.04.011
文献标识码:
A
摘要:
目的探讨复方斑蝥注射液对中晚期结直肠癌患者TGF-β1表达的影响。方法选取潍坊市中医院肿瘤中心收治的中晚期结直肠癌患者92例,随机分为2组,每组各46例。对照组采用FOLFOX4化疗方案治疗,治疗组在化疗基础上联合复方斑蝥注射液,分别检测治疗前及治疗1、2、3个周期后两组患者血清TGF-β1水平以及评价近期临床疗效。结果在化疗进行到第1、2、3周期时,两组患者血清中TGF-β1水平均有所改善,治疗组与对照组比较水平显著降低,差异有统计学意义(P<0.05);近期临床疗效治疗组在客观反应率(ORR)和疾病控制率(DCR)上均高于对照组,但差异无统计学意义(P>0.05)。结论复方斑蝥注射液能下调结直肠癌组织中的TGF-β1的表达水平,抑制肿瘤的生长、浸润,其作用机制可能与肿瘤血管的抑制和癌细胞的死亡有关,具有良好的临床疗效。
Abstract:
Objective To investigate the compound cantharis injection TGF-beta1 expression in patients with locally advanced colorectal cancer. Methods Selection of locally advanced colorectal cancer patients admitted in Weifang hospital cancer center, 92 cases were randomly divided into 2 groups, each group of 46 cases respectively. Control group adopts FOLFOX4 chemotherapy treatment, the treatment group on the basis of chemotherapy combined compound cantharis injection, respectively to observe before treatment and after treatment 1, 2, 3, cycle two groups of patients, and serum levels of TGF-beta1 evaluate recent clinical curative effect. Results Two groups in chemotherapy to 1, 2, 3 cycles, two groups of TGF-beta1 level in serum of patients improved, the treatment group were significantly reduced compared with controls, the difference was statistically significant(P<0.05);Recent clinical efficacy of the treatment group in objective response rate(ORR) and disease control rates are higher than the control group(DCR), but there was no statistically significant difference(P>0.05). Conclusion Compound cantharis injection could cut colorectal cancer TGF-beta1 expression level in the organization, and inhibit tumor growth, invasion, the action mechanism may be related to the inhibition of tumor blood vessels and the death of cancer cells, has the good clinical curative effect.

参考文献/References

[1] 郑树,万德森. 结直肠癌[M]. 北京:北京大学医学出版社,2008:33-35.
[2] 邓立春,沈伟生,张瑶,等. 化疗对晚期结直肠癌患者血清VEGF水平的影响[J]. 实用临床医药杂志,2010,14(5):90-91.
[3] 吴久鸿,史宁,李冠群,等. 肿瘤上皮间质转化中TGF-β作用机制及其活化酶抑制剂研究进展[J]. 中国药学杂志,2011,46(9):1461-1465.
[4] 陈文海,田逸,师彦敏,等. 中西医结合治疗晚期结肠癌疗效观察[J]. 现代中西医结合杂志,2014,23(11):1172-1174.
[5] Wang KS,Hu ZL,Li JH,et al. Enhancement of me-tastatic and invasive capacity of gastric cancer cells by transforming growth factor-beta1[J]. Acta Biochim Biophys Sin,2006,38(3):179-186.
[6] Lin Y,Kikuchi S,Obata Y,et al. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer[J]. J Gastroenterol Hepatol,2006,21(2):432-437.
[7] Saltzman BS,Yamamoto JF,Decker R,et al. Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neo-plasia[J]. Cancer Res,2008,68(4):1 236-1244.
[8] Zhou R,Xiong B,Song H,et al. Soluble transforming growth factor beta type II receptor attenuates TGF-be-ta1 activity in human colorectal cancer LoVo cells[J]. Oncol Rep,2008, 20(6):1449-1456.
[9] 张伟,胡可胜,孙续国. TGF-β1对单核细胞来源的树突状细胞表型和功能的影响[J]. 细胞与分子免疫学杂志,2009,25(12):1101-1102.
[10] Saito H,Tsujitani S,Oka S,et al. The expression of transformating growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of pa-tients with advanced gastric carcinoma[J]. Cancer,1999,86(8):1455-1462.
[11] 李佩文. 中医药对维护肿瘤患者生活质量的作用[J]. 中华肿瘤杂志,2002,24(2):203-204.
[12] 安宁,朱文. 人参皂苷Rg3抗肿瘤作用机制研究进展[J]. 现代肿瘤医学,2008,16(4):648-652.
[13] 王兵,高勇,许青,等. 人参皂苷Rg3对肺癌诱导血管内皮细胞增殖的抑制作用[J]. 中国新药杂志,2002,11(9):700-702.
[14] 张晶,刘芳芳,陈彦池,等. 刺五加化学成分及药理学研究进展[J]. 中国野生植物资源,2008,27(2):6-10.
[15] 莫日根,牛建昭,王继峰,等. 去甲斑蝥素对人脐静脉内皮细胞株的细胞毒作用[J]. 北京中医药大学学报,2001,24(6):25-28.
[16] 张蕻,梁小军,朴晋华,等. 复方斑蝥胶囊体内外抗肿瘤作用的实验研究[J]. 山西中医学院学报,2003,4(2):17-19.
[17] 何福根,章红燕,沈斌. 半枝莲抗肿瘤作用及其机制研究进展[J]. 中国肿瘤,2008,17(2):108-112.
[18] 李晓勇,刘少平. 结直肠癌患者血清TGF-β1的检测及临床意义[J]. 广西医科大学学报,2011,28(1):82-84.

备注/Memo

备注/Memo:
* 基金项目: 国家自然科学基金(81273987,81473513);山东省自然科学基金(ZR2011HQ050) 收稿日期: 2016 - 05 - 11 作者简介: 刘冰心(1989-),女,山东潍坊人,在读硕士研究生,研究方向:恶性肿瘤与血液病的中西医结合治疗。△通信作者:孙长岗,E-mail:zhongliuyike@163.com
更新日期/Last Update: 2016-07-20